Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Coeptis Therapeutics Hldgs Inc (COEP)

Coeptis Therapeutics Hldgs Inc (COEP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,965
  • Shares Outstanding, K 41,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,270 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta -0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings $-0.05 on 11/13/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1825 +4.05%
on 11/07/24
0.2410 -21.20%
on 10/22/24
-0.0321 (-14.46%)
since 10/21/24
3-Month
0.1511 +25.68%
on 09/27/24
0.2410 -21.20%
on 10/22/24
-0.0221 (-10.42%)
since 08/21/24
52-Week
0.1511 +25.68%
on 09/27/24
1.2800 -85.16%
on 12/04/23
-0.9801 (-83.77%)
since 11/21/23

Most Recent Stories

More News
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

/PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy...

COEP : 0.1899 (-1.96%)

Business Summary

Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp.,...

See More

Key Turning Points

3rd Resistance Point 0.2012
2nd Resistance Point 0.1981
1st Resistance Point 0.1940
Last Price 0.1899
1st Support Level 0.1868
2nd Support Level 0.1837
3rd Support Level 0.1796

See More

52-Week High 1.2800
Fibonacci 61.8% 0.8488
Fibonacci 50% 0.7156
Fibonacci 38.2% 0.5823
Last Price 0.1899
52-Week Low 0.1511

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar